Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis
about
An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling In Vitro.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsH-Ras regulation of TRAIL death receptor mediated apoptosisBax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient.Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor TherapeuticRuxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROSSynergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells.Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL.N-terminal gelsolin fragment potentiates TRAIL mediated death in resistant hepatoma cellsInnate immunodeficiency following genetic ablation of Mcl1 in natural killer cells.Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.Involvement of AMP-activated protein kinase and Death Receptor 5 in TRAIL-Berberine-induced apoptosis of cancer cells.Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer.
P2860
Q33611614-9CB24058-9F53-4645-A76D-3048F6B82D1FQ33756991-205AD2FD-A82A-41E4-8B1E-A0127EA262FEQ34104161-CFBCF11F-80D9-4B1E-8AFF-4C12936E3850Q36268430-93ED7BCF-9553-4998-8767-5976A7468AADQ36985683-DD54DEB1-D556-4A1B-8913-11CD7E65FD12Q36995729-D48C0581-86E3-48B4-9552-ECC46E6C1077Q37109457-68DF0145-6F9C-4031-BC2B-0B57E638F9AAQ37613829-6231E2DB-3E37-4AEC-B1C1-F5027D3277FBQ38708598-89527365-DA91-4C03-89B7-0A27F40F8241Q38902765-499BCA8D-1C0E-49DD-B428-3594A633F793Q38994016-4A03D049-FFE4-4DD0-AC3A-F80F247A586FQ42373863-F517D80B-BFE4-4EA5-AC6D-970B1845D329Q45301087-64201815-3CA6-4DD8-A720-65FA5C8F1D6EQ48096856-83274EE6-4FAB-420D-B10A-5C25D2B6E63CQ50944606-23896F32-45D5-40E2-9885-ADC057F14554Q52721892-07E0C44C-7B0A-4F65-8454-8DAA4088820EQ53570001-2A5C3581-3A43-4673-9DDF-9B902A14CC08Q55504441-E7B01F68-0987-463A-A2E8-1C557569B585
P2860
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Sorafenib sensitizes solid tum ...... es by the Jak2-Stat3-Mcl1 axis
@ast
Sorafenib sensitizes solid tum ...... es by the Jak2-Stat3-Mcl1 axis
@en
type
label
Sorafenib sensitizes solid tum ...... es by the Jak2-Stat3-Mcl1 axis
@ast
Sorafenib sensitizes solid tum ...... es by the Jak2-Stat3-Mcl1 axis
@en
prefLabel
Sorafenib sensitizes solid tum ...... es by the Jak2-Stat3-Mcl1 axis
@ast
Sorafenib sensitizes solid tum ...... es by the Jak2-Stat3-Mcl1 axis
@en
P2093
P2860
P1433
P1476
Sorafenib sensitizes solid tum ...... es by the Jak2-Stat3-Mcl1 axis
@en
P2093
Charles D Smith
David Goldenberg
David T Dicker
Joshua E Allen
Junaid Abdulghani
Robin Humphreys
Yingqiu Yvette Liu
P2860
P304
P356
10.1371/JOURNAL.PONE.0075414
P407
P577
2013-09-26T00:00:00Z